streptococci. The antibacterial effect of moxifloxacin was assessed by simulating changing concentrations of antibiotic in an in-vitro pharmacodynamic model of infection. As in previous studies the serum concentrations of moxifloxacin associated with doses of 400 mg administered once a day were modelled, as this is the dose of moxifloxacin used most commonly in human clinical trials.
Materials and methods

In-vitro model
An in-vitro model (New Brunswick Bioflo 1000; Hatfield, UK) was used to simulate oral administration of moxifloxacin 400 mg every 24 h over 48 h; i.e. two simulated doses. The apparatus consists of a single central culture chamber connected via aluminium and silicone tubing first to a dosing chamber (which is in turn connected to a reservoir containing broth) and secondly to a vessel collecting outflow broth from the central chamber. The dosing chamber and central culture chamber were diluted with broth from the reservoir using a peristaltic pump (Ismatec Bennett & Co, Weston-super-Mare, UK) at a flow rate of 66 mL/h, to simulate the decline in antibiotic concentration. The temperature was maintained at 37ºC and the broth in the dosing and central chambers was agitated by a magnetic stirrer.
Media
Brain Heart Infusion (BHI) broth (75%) (Unipath, Basingstoke, UK), supplemented with haemin 10 mg/L and -nicotinamide adenine dinucleotide 10 mg/L and L-histidine 10 mg/L, was used for the experiment with -haemolytic streptococci, and 6% IsoSensitest broth (ISB) (Unipath) was used for S. aureus. Preliminary investigations indicated that these broths supported a growth density of 5 10 7 -5 10 8 cfu/mL 18 h after inoculation into the model. Magnesium chloride at 1% (BDH, Poole, UK) was incorporated into nutrient agar plates (Merck, Poole, UK) containing 5% whole horse blood (TCS Microbiology, Buckingham, UK) to neutralize moxifloxacin before viable counts were determined.
Strains
S. aureus SMH 13942, methicillin and ciprofloxacin sensitive; S. aureus SMH 251, methicillin resistant, ciprofloxacin sensitive; Group A streptococcus SMH 14200 and Group G streptococcus SMH 14230 were used. Strains 13942M and 14200M were laboratory-generated mutants of strains 13942 and 14200 that were produced by the method of Dalhoff et al. 1 Briefly this method involves serial passage through antibiotic-containing broth, using bacterial isolates that grow at or around the MIC value.
Antibiotic
Moxifloxacin was obtained from Bayer AG, Wuppertal, Germany. Stock solutions were prepared according to The British Society of Antimicrobial Chemotherapy (BSAC) guidelines 9 and stored at -70ºC.
MICs
MICs were determined by the BSAC-defined standard broth dilution method 9 modified to use moxifloxacin concentrations that decreased by 0.2 mg/L or 0.02 mg/L steps rather than doubling dilutions.
Pharmacokinetics and bacterial killing curves
The in-vitro activity of changing concentrations of moxifloxacin against the six strains was tested in the model described above. Concentrations were chosen to simulate serum concentrations in man after a 400 mg oral dose every 24 h (to give a target peak serum concentration of 2.5 mg/L at 2 h post dose and a 24 h post-dose concentration of 0.4 mg/L 10 ). The area under the curve (AUC) was 24.4 mg/L. For all the experiments, 100 L of an overnight broth suspension of the test organism was inoculated into the central culture chamber via an entry port (initial inoculum of about 10 6 cfu/mL) and the model run for 18 h to allow equilibrium to be attained at a density of about 5 10 7 -5 10 8 cfu/mL. Moxifloxacin (1332 L of a 1 g/L solution) was then added to the dosing chamber at time 0, and at 24 h. Samples were taken from the central chamber via a port throughout the 48 h period (at times 0, 1, 2, 3, 4, 5, 6, 7, 10, 12, 22, 24, 25, 26, 27, 28, 29, 30, 31, 34, 36, 46 and 48 h) for assessment of viable bacterial count. The bacteria were counted without dilution and after 1/100 dilution using a spiral plater (Don Whitley Spiral Systems, Shipley, UK). The minimum detection level was 2 10 2 cfu/mL. In addition, aliquots were taken at the same time intervals and stored at -70ºC for measurement of moxifloxacin concentration. Samples were assayed by bioassay using Escherichia coli NCTC 10418 as indicator organism. 11 All standards and samples were prepared and diluted as necessary in the same concentration of BHI or ISB as that used in the model simulations. The limit of detection was 0.03 mg/L. All pharmacokinetic simulations and bacterial killing experiments were performed at least three times.
Pharmacokinetics, pharmacodynamic measurement of antibacterial effects and statistical analysis
Antibacterial activity was assessed by calculating the log change in viable count compared with time 0 at 12 h ( 12), 24 h ( 24), 36 h ( 36) and 48 h ( 48). In addition, the maximum reduction in viable count was recorded ( max). The area under the bacterial killing curve (AUBKC, log cfu/mL.h) was calculated, after the inoculum was standardized, by the log-linear trapezoidal rule for the time periods 0-24 h (AUBKC 2 4 ) and 0-48 h (AUBKC 4 8 
Results
Pharmacokinetic data
Moxifloxacin was detected at a concentration of 2.3 0.5 mg/L at 2 h and 0.5 0.1 mg/L at 24 h. These levels correlated well with those expected.
Bacterial killing curves
The killing curves for S. aureus after exposure to moxifloxacin are shown in Figures 1 and 2 . For the two strains with moxifloxacin MIC 0.14 mg/L there was a marked reduction in viable count (6 log) at 36 h with no regrowth occurring up to 48 h. In contrast, killing of the laboratorygenerated mutant (MIC 1.0 mg/L) was reduced (2 log reduction in count), with marked regrowth between 36 and 48 h. The AUBKC values were less for the more susceptible strains when compared with the mutant strains, especially AUBKC 48 . Results for the Group A streptococci tested showed that the more susceptible strain (MIC 0.16 mg/L) was killed more rapidly (3.5 log 10 ) with no regrowth. The mutant strain (MIC 1.8 mg/L) showed marked regrowth (2 log) and was poorly killed between 0 and 24 h (Figure 3 ). For these simulations a significant between-experiment variability was exhibited (Figure 3 and Table) . Killing of Group G streptococci (MIC 0.4 mg/L) was poor, with only a 2 log reduction in count over 48 h (Figure 4 and Table) .
Pharmacodynamics of the antibacterial effect
Curve fitting using an inhibitory E max sigmoidal model indicated that T MIC was poorly related to AUBKC 24 and AUBKC 48 tion of the residual plots was satisfactory. The maximum response, i.e. the lowest plateau AUBKC, occurs at an AUC/MIC ratio of 150.
Discussion
Previous data have indicated that moxifloxacin may be less bactericidal for Group A streptococci than for S. aureus even if allowance is made for differing MIC values. 4 Our data support this view-killing of a Group A streptococcus (MIC 0.16 mg/L) was remarkably less than that of a strain of S. aureus with an MIC of 0.14 mg/L. At higher MICs, no differences were observed, probably because moxifloxacin was not especially bactericidal for either species. While other data from in-vitro models are mostly lacking for S. aureus or -haemolytic streptococci, it is clear that moxifloxacin at in-vitro doses of 400 mg/24 h is rapidly bactericidal for S. pneumoniae with MICs 0.5 mg/L. 5, 6 In these experiments -haemolytic streptococci, Lancefield Group A MIC 0.16 mg/L or Group G MIC 0.4 mg/L, were not eradicated after two exposures to moxifloxacin. In contrast, using the same model, we were able to demonstrate significant bactericidal action of moxifloxacin at up to 36 h, using S. pneumoniae strains with MICs 0.5 mg/L. 5 Using simulations of 100 mg or 200 mg single doses, it has been shown previously that S. aureus can be eradicated from an in-vitro model within 12 h of dosing. 13 Our data confirm that there is significant bactericidal activity at 36-48 h for S. aureus strains with MICs 0.14 mg/L.
Animal data, in which E. coli, Klebsiella pneumoniae, S. aureus and S. pneumoniae are used in neutropenic mouse models of lung or thigh infection, have indicated that the dose required to produce a net bacteriostatic effect over 24 h is unchanged, whether moxifloxacin is given every 3, 6 or 12 h. In mice, moxifloxacin has a serum half-life of 1 h compared with 12-15 h in man. This probably indicates that once-daily dosing will be as effective as twice daily or more frequent doses. Drug AUC correlated with antibacterial efficacy more strongly than did C max or T MIC.
14 Furthermore, in an experimental animal model of S. pneumoniae meningitis, the drug AUC in cerebrospinal fluid correlated with the change in viable count. 15 Previous studies by this group, using the model system described here, have shown that the antibacterial effect of moxifloxacin correlated best with AUC/MIC for H. influenzae and M. catarrhalis.
18 These data also show that AUC parameters correlate best with antimicrobial effect, whether this be AUC/MIC, (AUC MIC)/MIC or WAUC. T MIC is not a good predictor using an inhibitory sigmoidal E max model, and WAUC here was not superior to the other parameters as has been postulated recently. 12 This is perhaps not surprising, as T MIC is an integral part of WAUC. As this study is not of a dose fractionation or escalation design, it was not possible to define the relative roles of C max /MIC ratio in comparison with AUC/MIC, despite recent interest in this area. 16 In conclusion, moxifloxacin has marked bactericidal action against S. aureus with MICs 0.14 mg/L but may be less bactericidal against -haemolytic streptococci; AUCbased pharmacodynamic factors predict antibacterial effect better than does T MIC.
